Panel Discussion: Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization

• At what point in therapeutic development should a sponsor begin thinking seriously about a CDx strategy and what are signs that teams may already be late?
• How are technologies such as digital pathology, NGS, liquid biopsy, multiplex testing, AI-enabled analysis, or bioinformatics changing the traditional CDx development model? 
• What needs to change in how pharma and diagnostic companies collaborate to make CDx development more efficient, globally scalable, commercially successful, and ultimately better for patients? 

Speakers:

Amy Wehn

Executive Director & Head, Companion Diagnostics and Clinical Biomarkers

Tango Therapeutics

Karina Kulangara

Vice President, Research & Development, Companion Diagnostics Associate

Agilent Technologies

Jeffrey Emch

Global Assistant VP, Precision Medicine In-Line Products, Oncology Marketing

Merck

Alyssa Tarzia

Regulatory

Agilent Technologies